The return to a more stable trade environment may create a short-term tailwind for small stocks, particularly those that derive the bulk of their revenues within the U.S.
Wall Street fought for a fifth consecutive day of gains on Friday, with major indexes edging slightly higher by midday in New York as investors continued to digest the week's significant trade breakthroughs and recalibrate their economic expectations.
CEO Gary Dickerson said the company is well positioned at major technology inflections in fast-growing market areas, which supports its multi-year growth trajectory.
U.S. stocks traded mixed Thursday, with major indices posting timid midday gains as investors digested fresh economic data revealing signs of consumer strain and disinflationary pressure stemming from April's tariff escalation.
While some longer-term measures still reflect strength, the short-term internal weakness suggests the market could be due for further consolidation or a deeper pullback, unless leadership broadens again.
San Francisco Fed President Mary Daly said the economy is on solid footing and reinforced the central bank's ability to respond to any government initiatives.
Over the past several trading sessions, market breadth has shown a clear and encouraging shift toward strength, particularly in the short to medium term.
A fund manager expects huge amounts of investment funds and the fear of missing out to bring new buyers, especially if progress continues on the tariff front and the inflation impact is less than feared.
The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.
Wall Street's rally stretched into a second session Tuesday, fueled by improving investor sentiment after an early-week breakthrough in U.S.-China trade talks, easing inflation data and fresh geopolitical headlines involving major investment pledges from the Middle East.
In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).
Tariff news flow, first-tier economic data, and a few earnings reports could decide the day's trading direction, although the momentum is decisively in favor of further gains.
The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.
U.S. Trade Representative Jamieson Greer stated that the speed with which the U.S. and China could reach an agreement showed that perhaps the differences were not as large as initially thought.
